Search Results - "Ruhlmann, C.H."

2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients by Roila, F, Molassiotis, A, Herrstedt, J, Aapro, M, Gralla, R J, Bruera, E, Clark-Snow, R A, Dupuis, L L, Einhorn, L H, Feyer, P, Hesketh, P J, Jordan, K, Olver, I, Rapoport, B L, Roscoe, J, Ruhlmann, C H, Walsh, D, Warr, D, van der Wetering, M

Get full text

34LBA Fosaprepitant for the prevention of nausea and emesis during five weeks of chemo-radiotherapy: A multinational randomised, placebo-controlled, double-blind trial – the GAND-emesis study by Ruhlmann, C.H, Christensen, T.B, Dohn, L.H, Paludan, M, Rannengart, E, Hilpert, F, Feyer, P, Kristensen, G, Keefe, D, Hansen, O, Herrstedt, J

Get full text

2078P Evaluation of chemotherapy-induced nausea and vomiting beyond the delayed phase: Results of a survey of healthcare providers in Japan by Scotté, F., Aapro, M.S., Ruhlmann, C.H., Takeuchi, Y.

Get full text

455P Assessing model-predicted neurokinin-1 (NK1) receptor occupancy (RO) of netupitant to support efficacy over an extended time period by Scotté, F., Zelek, L., Giuliano, C., Olivari Tilola, S., Bailey, W.L., Ruhlmann, C.H., Iihara, H., Aapro, M.S.

Get full text

1156P Immune-related adverse events in a nationwide cohort of melanoma patients treated with adjuvant anti-PD1: Seasonal variation and association with outcome by Ellebæk, E., Jurlander, R.S., Guldbrandt, L.M., Holmstroem, R.B., Donia, M., Haslund, C.A., Schmidt, H., Bastholt, L., Ruhlmann, C.H., Svane, I-M.

Get full text

1071P A nationwide, real-life study of outcome and quality of life after the introduction of adjuvant immunotherapy for Danish melanoma patients by Ellebaek, E., Holmstrøm, R.B., Ruhlmann, C.H., Schmidt, H., Haslund, C.A., Donia, M., von Heymann, A., Johansen, C., Bastholt, L., Svane, I.M.

Get full text

OC-0751 Collecting Complete Radiotherapy Plan Data of 11,000+ Patients in a National Database by Krogh, S., Lorenzen, E., Hansen, C.R., Samsøe, E., Vogelius, I.R., Zukauskaite, R., Offersen, B.V., Eriksen, J.G., Hansen, O., Johansen, J., Olloni, A., Ruhlmann, C.H., Hoffmann, L., Nissen, H.D., Nielsen, M.S., Andersen, K., Grau, C., Brink, C.

Get full text

Fosaprepitant reduces the impact of nausea on daily function during five weeks of chemo-radiotherapy: A sub-study of the GAND-emesis trial by Ruhlmann, C.H., Christensen, T.B., Hammer Dohn, L., Paludan, M., Roennengart, E., Hilpert, F., Feyer, P., Kristensen, G., Hansen, O., Keefe, D., Herrstedt, J.

Get full text

2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting by Herrstedt, J., Clark-Snow, R., Ruhlmann, C.H., Molassiotis, A., Olver, I., Rapoport, B.L., Aapro, M., Dennis, K., Hesketh, P.J., Navari, R.M., Schwartzberg, L., Affronti, M.L., Garcia-Del-Barrio, M.A., Chan, A., Celio, L., Chow, R., Fleury, M., Gralla, R.J., Giusti, R., Jahn, F., Iihara, H., Maranzano, E., Radhakrishnan, V., Saito, M., Sayegh, P., Bosnjak, S., Zhang, L., Lee, J., Ostwal, V., Smit, T., Zilic, A., Jordan, K., Scotté, F.

“…•Nausea and vomiting are considered amongst the most troublesome adverse events for patients receiving antineoplastics.•The guideline covers emetic risk…”
Get full text